Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Interest Expense

Cost of servicing the company's debt during the period.

SanofiNASDAQ: SNY

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of €287M rose 42.5% year over year, ahead of the -39.7% change in trailing-twelve-month interest expense. Sequentially, it rose 61.2% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Interest expense amounted to 1.3% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +42.5% holds above the trailing-twelve-month pace of -39.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€287M+61.2% QoQ
Last fiscal yearDec 2025
€626M+0.6% YoY
LTMJun 2026
€591.41M-39.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.5%——
1 year+0.6%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
626M EUR
Year-over-year change
+0.6%
4-year CAGR
+13.5%

Interest Expense vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.7% is the 10th highest of 11, against a peer median of -0.7%.
  • Interest expense amounts to 1.2% of revenue for SNY, versus a peer median of 2.7%.
SNY Competitors
Interest Expense for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 5B DKK-68.9%+123.3%1.5%
PFEPfizer Inc.LTM Jun 2026$2.7B USD-4.7%+29.2%4.2%
AMGNAmgen Inc.LTM Jun 2026$2.67B USD-9.7%+25.1%7.0%
AZNAstraZeneca PLCLTM Sep 2026$1.77B USD+7.2%+8.4%2.8%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$1.73B USD-12.6%+15.4%3.5%
NVSNovartis AGLTM Jun 2026$1.39B USD+26.0%+12.5%2.5%
MRKMerck & Co., Inc.LTM Jun 2026$1.26B USD-1.0%+12.2%1.9%
GILDGilead Sciences, Inc.LTM Jun 2026$998M USD-0.3%+3.1%3.3%
LLYEli Lilly and CompanyLTM Jun 2026$979.6M USD+7.6%+33.9%1.2%
GSKGSK plcLTM Jun 2026£690M GBP+6.8%-7.1%2.1%
SNYSanofiLTM Jun 2026€591.41M EUR-39.7%+17.6%1.2%
Peer median (excluding SNY) —-0.7%+13.9%2.7%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.